Alector, GSK Partner to Develop 2 Therapies for Dementia

Alector, GSK Partner to Develop 2 Therapies for Dementia

298473

Alector, GSK Partner to Develop 2 Therapies for Dementia

Alector and GlaxoSmithKline (GSK) will collaborate in developing and commercializing two therapies aimed at treating an uncommon type of dementia that can cause problems with behavior and language. Both investigational therapies — AL001 and AL101 — can be used across a range of neurodegenerative disorders, including Parkinson’s, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease, the companies said in a press release. The medications are designed to boost the body’s levels of progranulin (PGN), a key regulator…

You must be logged in to read/download the full post.